Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study

Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.

[1]  H. Adami,et al.  Immediate Risk for Cardiovascular Events and Suicide Following a Prostate Cancer Diagnosis: Prospective Cohort Study , 2009, PLoS medicine.

[2]  A. Tonevitsky,et al.  Transcriptome of Extracellular Vesicles: State-of-the-Art , 2019, Front. Immunol..

[3]  V. Tombolini,et al.  Psychological and functional effect of different primary treatments for prostate cancer: A comparative prospective analysis. , 2018, Urologic oncology.

[4]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[5]  Carla Oliveira,et al.  Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. , 2016, ACS nano.

[6]  R. Hoffman,et al.  Clinical practice. Screening for prostate cancer. , 2011, The New England journal of medicine.

[7]  Alessandro Giuliani,et al.  The application of principal component analysis to drug discovery and biomedical data. , 2017, Drug discovery today.

[8]  Z. Giricz,et al.  Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods , 2015, PloS one.

[9]  H. Nielsen,et al.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.

[10]  Alessandro Sciarra,et al.  Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients. , 2017, Cancer letters.

[11]  Hans Lilja,et al.  Serum markers for prostate cancer: a rational approach to the literature. , 2008, European urology.

[12]  H. Lilja.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[13]  G. Jenster,et al.  Immuno‐based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer , 2015, International journal of cancer.

[14]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[15]  Tushar Patel,et al.  Circulating Extracellular Vesicles in Human Disease. , 2018, The New England journal of medicine.

[16]  Andrew J Vickers,et al.  Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen , 2014, BMC Medicine.

[17]  Graça Raposo,et al.  Exosomal-like vesicles are present in human blood plasma. , 2005, International immunology.

[18]  Graça Raposo,et al.  Shedding light on the cell biology of extracellular vesicles , 2018, Nature Reviews Molecular Cell Biology.

[19]  M. Logozzi,et al.  Exosomes: the ideal nanovectors for biodelivery , 2013, Biological chemistry.

[20]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[21]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[22]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[23]  C. Catalano,et al.  Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. , 2015, Urologic oncology.

[24]  A. Molinari,et al.  Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells* , 2009, The Journal of Biological Chemistry.

[25]  Mario Falchi,et al.  Microenvironmental pH and Exosome Levels Interplay in Human Cancer Cell Lines of Different Histotypes , 2018, Cancers.

[26]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[27]  E. Feuer,et al.  Studies of prostate-cancer mortality: caution advised. , 2008, The Lancet. Oncology.

[28]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[29]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[30]  A. Guha,et al.  Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells , 2008, Nature Cell Biology.

[31]  K. Pienta,et al.  The evolving biology and treatment of prostate cancer. , 2007, The Journal of clinical investigation.

[32]  Joanne L Welton,et al.  Can urinary exosomes act as treatment response markers in prostate cancer? , 2009, Journal of Translational Medicine.

[33]  M. Logozzi,et al.  A Pilot Clinical Study on the Prognostic Relevance of Plasmatic Exosomes Levels in Oral Squamous Cell Carcinoma Patients , 2019, Cancers.

[34]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[35]  L. O’Driscoll,et al.  Biological properties of extracellular vesicles and their physiological functions , 2015, Journal of extracellular vesicles.

[36]  A. Marcilla,et al.  Reprint of “EXOSOME LEVELS IN HUMAN BODY FLUIDS: A TUMOR MARKER BY THEMSELVES?”☆ , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  Francesco Cappello,et al.  Exosome levels in human body fluids: A tumor marker by themselves? , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[38]  Massimo Spada,et al.  High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients , 2009, PloS one.

[39]  T. D. de Reijke,et al.  Prostate cancer biomarker profiles in urinary sediments and exosomes. , 2014, The Journal of urology.

[40]  C. Moore,et al.  MRI-Targeted Biopsy for Prostate-Cancer Diagnosis. , 2018, The New England journal of medicine.